Latest Keryx Biopharmaceuticals (KERX) Headlines
Post# of 39
Posted On: 03/12/2014 10:54:46 PM
Latest Keryx Biopharmaceuticals (KERX) Headlines
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"), today announced its financial results for the fourth quarter and year ended December 31, 2013.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Tue Mar 11, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December 31, 2013 and a business outlook for 2014. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
Keryx Biopharmaceuticals submits Zerenex's MAA to EMA seeking approval for treating CKD patients
M2 - Tue Mar 11, 4:34AM CDT
Pharmaceutical company Keryx Biopharmaceuticals (NasdaqCM:KERX) disclosed on Monday the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the treatment for hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis- and non-dialysis dependent CKD.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), seeking the approval of Zerenex(TM) (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis dependent CKD.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
93.8% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Mar 05, 4:41PM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 93.78% as of today's recent price of $16.50.
Keryx Biopharmaceuticals Up 98.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 26, 10:57AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 98.83% as of today's recent price of $16.93.
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Keryx Biopharmaceuticals Up 81.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 19, 9:36AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 81.68% as of today's recent price of $15.47.
Keryx Biopharmaceuticals Inc names Abraham Ceesay as vice president of Marketing
M2 - Wed Feb 19, 3:46AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Tuesday that it has elected Abraham Ceesay as vice president of its Marketing and Operations.
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing
Thomson Reuters ONE - Tue Feb 18, 7:30AM CST
NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of Abraham Ceesay as Vice President of Marketing and Operations. In this role, Mr. Ceesay will develop and lead all aspects of the ZerenexTM launch strategy and execution, including brand planning, forecasting and analysis, marketing operations and patient access programs. The Company's new drug application for Zerenex (ferric citrate coordination complex) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014.
Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters
PR Newswire - Fri Feb 14, 11:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/77j8t4/demand_outlook) has announced the addition of the "Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters" report to their offering.
Keryx Biopharmaceuticals Has Returned 81.0% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Wed Feb 12, 9:10AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 80.97% as of today's recent price of $15.41.
Keryx Biopharmaceuticals elects Greg Madison as COO to lead commercialisation effort for Zerenex
M2 - Tue Feb 11, 7:06AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Monday the addition of Greg Madison as executive vice president and chief operating officer.
Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer
Thomson Reuters ONE - Mon Feb 10, 7:31AM CST
Renal Industry Veteran to Lead Commercialization Effort for Zerenex
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"), today announced its financial results for the fourth quarter and year ended December 31, 2013.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Tue Mar 11, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December 31, 2013 and a business outlook for 2014. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
Keryx Biopharmaceuticals submits Zerenex's MAA to EMA seeking approval for treating CKD patients
M2 - Tue Mar 11, 4:34AM CDT
Pharmaceutical company Keryx Biopharmaceuticals (NasdaqCM:KERX) disclosed on Monday the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the treatment for hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis- and non-dialysis dependent CKD.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), seeking the approval of Zerenex(TM) (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis dependent CKD.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
93.8% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Mar 05, 4:41PM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 93.78% as of today's recent price of $16.50.
Keryx Biopharmaceuticals Up 98.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 26, 10:57AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 98.83% as of today's recent price of $16.93.
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Keryx Biopharmaceuticals Up 81.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 19, 9:36AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 81.68% as of today's recent price of $15.47.
Keryx Biopharmaceuticals Inc names Abraham Ceesay as vice president of Marketing
M2 - Wed Feb 19, 3:46AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Tuesday that it has elected Abraham Ceesay as vice president of its Marketing and Operations.
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing
Thomson Reuters ONE - Tue Feb 18, 7:30AM CST
NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of Abraham Ceesay as Vice President of Marketing and Operations. In this role, Mr. Ceesay will develop and lead all aspects of the ZerenexTM launch strategy and execution, including brand planning, forecasting and analysis, marketing operations and patient access programs. The Company's new drug application for Zerenex (ferric citrate coordination complex) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014.
Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters
PR Newswire - Fri Feb 14, 11:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/77j8t4/demand_outlook) has announced the addition of the "Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters" report to their offering.
Keryx Biopharmaceuticals Has Returned 81.0% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Wed Feb 12, 9:10AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 80.97% as of today's recent price of $15.41.
Keryx Biopharmaceuticals elects Greg Madison as COO to lead commercialisation effort for Zerenex
M2 - Tue Feb 11, 7:06AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Monday the addition of Greg Madison as executive vice president and chief operating officer.
Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer
Thomson Reuters ONE - Mon Feb 10, 7:31AM CST
Renal Industry Veteran to Lead Commercialization Effort for Zerenex
(0)
(0)